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Summary
The pathological mechanisms underlying the development of immune
thrombocytopenia (ITP) are unclear and its diagnosis remains a process of
exclusion. Currently, there are no known specific biomarkers for ITP to
support differential diagnosis and treatment decisions. Profiling of serum
proteins may be valuable for identifying such biomarkers. Sera from 46
patients with primary chronic ITP and 34 healthy blood donors were anal-
ysed using a microarray of 755 antibodies. We identified 161 differentially
expressed proteins. In addition to oncoproteins and tumour-suppressor
proteins, including apoptosis regulator BCL2, breast cancer type 1 suscepti-
bility protein (BRCA1), Fanconi anaemia complementation group C
(FANCC) and vascular endothelial growth factor A (VEGFA), we detected
six anti-nuclear autoantibodies in a subset of ITP patients: anti-PCNA,
anti-SmD, anti-Ro/SSA60, anti-Ro/SSA52, anti-La/SSB and anti-RNPC
antibodies. This finding may provide a rational explanation for the associa-
tion of ITP with malignancies and other autoimmune diseases. While
RUNX1 mRNA expression in the peripheral blood mononuclear cells
(PBMC) of patients was significantly downregulated, an accumulation of
RUNX1 protein was observed in the platelets of ITP patients. This may
indicate dysregulation of RUNX1 expression in PBMC and megakaryocytes
and may lead to an imbalanced immune response and impaired throm-
bopoiesis. In conclusion, we provide novel insights into the pathogenic
mechanisms of ITP that warrant further exploration.
Keywords: chronic autoimmune thrombocytopenic purpura, cancer, B cell
CLL/lymphoma 2, runt-related transcription factor 3, thrombocytopenia.
Autoimmune thrombocytopenia (ITP) is a well-defined dis-
order that develops spontaneously and without any known
causes (primary form). ITP also appears in association with
other conditions, such as infections, malignancies, other
autoimmune diseases and immunodeficiencies (secondary
form) (Sullivan et al, 1997; Liebman & Stasi, 2007; Rode-
ghiero et al, 2009; Stasi et al, 2009; Krauth et al, 2012).
A number of genetic associations (Wu et al, 2005; Emmerich
et al, 2007) have been identified and several well-known phe-
nomena have been demonstrated to occur in ITP, such as
autoantibodies (Harrington et al, 1951), T-cell mediated
cytotoxicity (Olsson et al, 2003), complement activation
(Cines & Schreiber, 1979), deficiency of platelet production
(Ballem et al, 1987), loss of peripheral immune tolerance
(Fogarty, 2011), dominant proinflammatory states (Guo
et al, 2007), and various B and T lymphocyte dysfunctions
(Olsson et al, 2005; Li et al, 2012). However, our under-
standing of ITP diagnosis, therapy, and pathogenesis remains
limited. Its diagnosis is one of exclusion, and symptomatic
treatment eases the symptoms without addressing the basic
cause of the disease.
The pathogenic mechanisms of chronic refractory ITP
(cITP) are complex and the initiating event remains elusive.
Due to the complexity of the immune system and hetero-
geneity of the disease, it is difficult to elucidate all factors
responsible for the development of cITP. Hitherto, only two
research paper
First published online 2 December 2015
doi: 10.1111/bjh.13861
ª 2015 John Wiley & Sons Ltd
British Journal of Haematology, 2016, 172, 602–615
candidate biomarkers have been reported in two studies to
support differential diagnosis and treatment decisions in ITP.
One of these studies, based on one-dimensional gel elec-
trophoresis and the quantitation of identified proteins by liq-
uid chromatography-tandem mass spectrometric analysis,
found significantly higher levels of ceruloplasmin in patients
with ITP compared with non-ITP patients and controls
(Chousa et al, 2008). A second study used two-dimensional
gel electrophoresis and found significantly lower haptoglobin
levels in ITP patients non-responsive to splenectomy than in
the responders (Zheng et al, 2012). However, the results of
both studies are clinically less conclusive and are limited due
to the techniques applied. Therefore, the present study
applied antibody microarray to identify potential factors in
the sera of patients and control individuals. Serum reflects
the body’s whole cellular metabolism and the release of pro-
teins from a particular organ or a group of cells into the cir-
culation due to physiological or pathophysiological
alterations.
cITP patients may not only develop serious bleeding, but
also other complications. The risk of haematological malig-
nancies, such as acute myeloid leukaemia (AML), chronic
lymphocytic leukaemia (CLL), Hodgkin lymphoma (HL),
and non-Hodgkin lymphomas (NHL), has been reported to
be significantly increased in cITP patients (Norgaard et al,
2011). On the contrary, immune-mediated platelet destruc-
tion is not uncommon in haematological malignancies
(Krauth et al, 2012). This secondary ITP has been identified
in some solid tumours and most lymphoproliferative disor-
ders, but is more prevalent in patients with AML, CLL, HL
and the myelodysplastic syndromes (MDS) (Cines et al,
2009; Liebman, 2009). This may be an indication of mutual
pathophysiological mechanisms in cITP and haematological
malignancies. A prediction of progression from cITP to
malignancies would be useful.
Due to the aforementioned increased risk of haematologi-
cal malignancies amongst patients with cITP, a set of onco-
proteomic antibodies strogly related to haematological
malignancies were selected for analysis. The present study
should provide new insights in the pathophysiological mech-
anisms associated with haematological malignancies in cITP
and therefore identify biomarkers that may improve differen-
tial diagnosis and support treatment decisions in ITP.
Materials and methods
Study design
cITP was diagnosed in accordance with the 2011 guidelines
of the American Society of Hematology (Neunert et al,
2011). All patients were in chronic phase of the disease and
had been under treatment in our centre for at least 1 year.
Blood samples from 46 patients and 34 healthy controls were
compared by proteomic profiling. Each patient was individu-
ally classified as being in active phase or remission phase
according to their clinical parameters, such as platelet count,
bleeding tendency, medication and prognosis. Active cITP
was diagnosed in 34 patients, whereas 12 patients were in
remission. Hereby, platelet counts were used as the main cri-
teria for definition of remission (>100 9 109/l) or active
phase (<100 9 109/l); bleeding tendency, altered platelet
counts before and after the sampling date were also used as a
decisive parameter to define the phase of disease as active or
remission. During the course of the study, participating
patients did not receive drugs known to induce thrombocy-
topenia. Anti-platelet autoantibodies were detected in 17
patients. Twenty patients were receiving immunosuppressive
therapy with glucocorticoids and azathioprine. Among the
remaining patients (n = 26), the spontaneous development
of the disease was left untreated because they did not
demonstrate an increased risk of severe bleeding; however,
six of these patients were splenectomized. A summary of the
study groups is provided in Table S1. Healthy control sub-
jects (n = 34) were volunteer blood donors who received no
drugs within 14 d prior to blood donation and had platelet
counts greater than 250 9 109/l. These values were measured
before donation. This study was approved by the Ethical
Institutional Review board of the Charite University Berlin,
Germany (EA2_130_09).
Further investigations
Findings from protein microarray analyses were further
investigated using enzyme-linked immunosorbent assay
(ELISA), line immunoassay (LIA) and Western Blot assays.
Due to a lack of material remaining after microarray analysis
of the first cohort, we performed further analyses with new
cohorts, which consisted partly of patients from the first
cohort mixed with new samples. VEGFA ELISA assays were
performed with 33 healthy controls and 46 patients with
cITP (33 active phase, 13 remission). LIA assays were per-
formed with 40 patients and 20 healthy controls.
Serum separation
Blood samples were collected in serum separating tubes (cat-
alogue number 367955, Becton Dickinson, Heidelberg, Ger-
many) that contained a gel to clearly separate serum from
cellular components without any anticoagulation. All samples
were processed under identical conditions. Sera were
obtained by centrifugation at 1500 g for 10 min. Protease
inhibitor cocktail (Complete Mini EDTA-free, Roche,
Mannheim, Germany) was used to inhibit protease activity.
Samples were frozen at 80°C until analysis.
Microarray preparation
Antibody microarrays were produced as previously described
(Alhamdani et al, 2010, 2012; Schroder et al, 2010). Briefly,
all antibodies were diluted to a final concentration of
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10 mg/ml in spotting buffer containing 100 mmol/l sodium
carbonate (pH 85), 5 mmol/l MgCl2, 001% (w/v) sodium
azide, 05% (w/v) dextran sulfate and 137 mmol/l sodium
chloride. Antibodies were spotted in quadruplicates on
epoxysilane slides (Schott Nexterion, Jena, Germany) using a
Microgrid microarraying robot (BioRobotics, Cambridge,
UK) with SMP3B pins (Telechem, Sunnyvale, USA). Anti-
bodies against b-actin (ACTB), human IgM, glyceraldehyde-
3-phosphate dehydrogenase and albumin were spotted as
controls. Negative controls consisting of only spotting buffer
were added, as well as additional control antibodies (e.g.
antibodies directed against mouse immunoglobulin gamma).
All controls were spotted in 8–18 copies across the entire
array to ensure a good distribution of controls for normal-
ization purposes. After printing, the slides were maintained
at 4°C and 50–60% humidity overnight. Printed slides were
stored in dry conditions at 4°C until use.
Sample labelling
The labelling of serum proteins was performed as previously
described (Alhamdani et al, 2010, 2012; Schroder et al,
2010). Briefly, serum samples were labelled at a 20 mg/ml
protein concentration with the N-hydroxysuccinimide esters
of the fluorescence dyes Dy-549 or Dy-649 (Dyomics, Jena,
Germany) at a dye/protein labelling ratio of 745 moles in
100 mm sodium carbonate buffer (pH 85) for 2 h with con-
stant shaking at 4°C in the dark. The labelling reaction was
stopped by adding 10% (w/v) glycine in sodium carbonate
buffer (100 mm, pH 85) and continuous shaking at 4°C for
an additional 20 min to quench the unreacted dye. Subse-
quently, complete protease inhibitor mixture tablets (Roche)
were added as recommended by the manufacturer. Labelled
samples were either incubated directly or stored as aliquots
at 20°C.
Protein array incubation
Each sample was incubated competitively with a common
reference that was made by a pool of all serum samples in
a dual-colour mode as previously described (Alhamdani
et al, 2012). Briefly, microarray slides were equilibrated to
room temperature for 20 min, transferred to Quadriperm
chambers (Greiner Bio-One, Frickenhausen, Germany), and
washed twice with phosphate-buffered saline (PBS) solution
containing 005% (w/v) Tween 20 for 5 min and 10 min.
Slides were blocked with 10% non-fat dry milk (Biorad,
Munich, Germany) prepared in PBS with 005% Tween 20
for 3 h at room temperature in the dark. Sample incuba-
tion was performed in the same chambers using 50 lg of
labelled proteins in 5 ml of PBS containing 005% Tween
20 and 10% non-fat dry milk overnight at 4°C in the
dark. Finally, the slides were washed four times for 5 min
each with PBS containing 005% Tween 20, rinsed thor-
oughly with distilled water, and dried in a ventilated oven
at room temperature. Scanning of the slides was performed
using a ScanArray 5000 unit (Perkin Elmer, Waltham,
USA) set at the identical instrument laser power and pho-
tomultiplier intensity in each experiment. Spot segmenta-
tion was performed using GenePix Pro 6.0 (Molecular
Devices, Sunnyvale, USA).
Platelet isolation
Platelet-rich plasma (PRP) was obtained from whole blood
taken into citrate-anticoagulated vacutainers by centrifuga-
tion at 200 g for 20 min at room temperature without brake.
The supernatant (PRP phase) was transferred into a new
tube and HEP buffer (140 mmol/l NaCl, 27 mmol/l KCl,
38 mmol/l HEPES, 5 mmol/l EGTA, pH 74) at a 1:1 ratio
(v/v) was added. After gently mixing, the samples were cen-
trifuged at 100 g for 15 min at room temperature. Super-
natants were transferred into a new tube and spun at 800 g
for 15 min at room temperature to pellet the platelets. Pellets
were washed once with PBS and then lysed in radioimmuno-
precipitation assay (RIPA) buffer with proteinase inhibitors
(Complete Mini EDTA-free, Roche, Germany) to produce
platelet protein lysates.
Immunoblotting of platelet RUNX1 and RUNX3
proteins
Protein lysates of platelet samples from study patients and
healthy controls were separated by sodium dodecyl sulphate
polyacryamide gel electrophoresis and transferred to nitrocel-
lulose membranes. The membranes were probed with anti-
bodies directed against RUNX1 (D33G6 XP Rabbit
monoclonal antibody cat no: #4336, Cell Signaling Technol-
ogy, Danvers, MA, USA) and RUNX3 (D6E2 Rabbit mAb,
Cell Signaling Technology). The corresponding band of each
protein was detected by referenced molecular weight using a
protein ladder.
Separation of peripheral blood mononuclear cells
(PBMC) and RNA isolation
PBMC separation and RNA isolation were performed using
samples from 12 cITP patients and 12 healthy controls.
PBMC were isolated from 9 ml of whole blood using a Ficoll
gradient (Biochrom AG, Berlin, Germany). Isolated PBMC
were lysed in Trizol (Invitrogen, Carlsbad, CA, USA) and
afterwards RNA was extracted as previously described
(Chomczynski & Sacchi, 1987).
Gene expression quantification
cDNA was synthesized from 2 lg of total RNA using the
high capacity RNA-to-cDNA master mix (Applied Biosys-
tems, Foster City, CA, USA) according to the manufacturer’s
protocol. The cDNAs were subjected to quantitative
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polymerase chain reaction (PCR) using SYBR Green Super-
mix (Applied Biosystems) and detected on the StepOnePlusTM
Real-Time PCR System (Applied Biosystems) platform. For
quantification, the DCt algorithm was applied using ACTB as
a housekeeping gene.
Measurement of serum levels of VEGFA
Vascular endothelial growth factor A (VEGFA) levels were
measured using a specific ELISA (PromoKine Human
VEGFA ELISA Kit, catalogue number: PK-EL-64406, Promo-
Cell, Heidelberg, Germany) using 50 ll of serum according
to the manufacturer’s recommendations. Serum levels of
VEGFA were calculated from a standard curve generated
using recombinant human VEGFA (PromoCell).
Line immunoassay (LIA)
The recomLine ANA/ENA IgG (Mikrogen, Neuried, Ger-
many) is a LIA that detects the presence of autoantibodies
against a variety of auto-antigens present in autoimmune dis-
eases (RNP68, RNPA, RNPC, SmB, SmD, Ro/SSA60, Ro/
SSA52, La/SSB, Rib-P, PCNA, CENP-B, scl70, Jo-1, histone,
and dsDNA). The test procedure was performed according to
the manufacturer’s instructions. Briefly, 20 ll of serum was
diluted at 1:100 and added on a test strip in an incubation
tray for 1 h. The test strip was then washed thrice and incu-
bated with peroxidase conjugated anti-human antibodies
(IgG-specific) for 45 min. After repeated washes, 15 ml of
the substrate solution was added and incubated for 8 min.
The strip was the washed thrice with deionized water and
the coloured bands that developed on the test strips were
analysed.
Bioinformatic analysis and statistics
Using analytical methods analogous to those for DNA
microarrays, the datasets were normalized using a quantile
normalization approach. The protein expression of cITP and
healthy controls was compared based on a linear model with
a common reference. Comparisons of the differences in pro-
tein expression between the groups were derived using the
empiric Bayes moderated t-test implemented in the linear
models using the Bioconductor software microarray data
(LIMMA) package (Smyth, 2004). P values were adjusted for
multiple testing using the Benjamini-Hochberg method.
Functional enrichment analysis of differentially expressed
protein was performed by categorizing proteins within the
annotations of the Gene Ontology (GO) using the Database
for Annotation, Visualization and Integrated Discovery
(DAVID, https://david.ncifcrf.gov/). Hereby, enrichment of
the protein in the GO was calculated based on 679 distinct
serum proteins spotted on our chips as a background dataset
(Huang da et al, 2009).
The student’s t-test and Mann-Whitney U test were used
to compare values of serum levels of VEGFA or RNA
expression values of VEGFA, RUNX1 and RUNX3. A P
value less than 005 was considered significant. Pearson’s
correlation coefficient was calculated to examine the associ-
ation between VEGFA levels and the platelet counts of
patients.
Results
Oncoproteomic profiling of serum samples
We performed antibody microarray analysis on serum sam-
ples from 46 cITP patients and 34 healthy controls using
755 antibody probes corresponding to 679 distinct target
proteins. In total, the expression of 165 probes, correspond-
ing to 161 distinct proteins, was significantly different in
the ITP group. To explore the biological significance of dif-
ferentially expressed proteins, we examined their enrichment
in the GO. Significant overrepresentation of proteins was
identified in several interesting GO categories including
‘blood coagulation’ (P = 001), ‘induction of apoptosis’
(P = 004), ‘activation of caspase activity’ (p = 004) and
‘DNA damage response, signal transduction’ (P = 003)
(Table S2).
The expression of many oncoproteins and tumour-sup-
pressor proteins, including HPV16 E1 protein-binding pro-
tein (TRIP13), breast cancer type 1 susceptibility protein
(BRCA1), Fanconi anaemia complementation group C
(FANCC), and breast carcinoma amplified sequence 1
(BCAS1), were significantly altered in the serum of cITP
patients. The expression of 77 proteins was decreased in ITP
patients including VEGFA, CDKN2A (P16INK4) and apopto-
sis regulator (BAX), whereas the expression of 84 proteins
was increased including Ewing sarcoma breakpoint region 1
protein (EWSR1), zinc finger protein 593 (ZNF593), and
regulator complex protein LAMTOR1 (C11orf59). Lists of
the 20 proteins with the highest fold increase and decrease
(adjusted P value < 005) in expression are presented in
Tables I and II.
To focus on differences between the patients in active or
remission phase versus the healthy control group, the
microarray data of both patient groups were analysed sepa-
rately. A total of 134 distinct proteins showed significant dif-
ferences between the active cITP and the healthy group
(Fig 1, Table S3). Only 10 of these proteins were also signifi-
cantly altered in the remission group. Interestingly, only
eight proteins, including B cell CLL/lymphoma 2 (BCL2),
interferon gamma (IFNG), fibroblast growth factor 2 (FGF2)
and cyclin-G1 (CCNG1), demonstrated active disease state-
specific changes in their serum abundance of cITP groups
(Fig 1). In hierarchical cluster analysis, 134 differentially
expressed proteins and 80 samples were grouped according
to their expression profiles. While most of the patients in
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active disease state and the healthy controls were assembled
as two groups, patients in remission did not form a separate
group but were found to rather distribute between healthy
controls and active ITP (Fig 2).
Analysis of VEGFA expression using ELISA and reverse
transcription PCR (RT-PCR)
In the antibody microarray data, VEGFA expression was
mostly decreased in the cITP group (215-fold change,
adjusted P = 001). To confirm this finding, we performed
ELISA for VEGFA on serum samples of 46 patients with ITP
and 33 healthy donors (Fig 3B). The serum levels of VEGFA
in patients with active ITP (median, 196 pg/ml) were signifi-
cantly lower (P = 0002) than in healthy controls (median,
648 pg/ml). In the remission group (n = 13), the levels of
VEGFA were found to be similar to those of the healthy con-
trol group (median, 579 pg/ml). The correlation coefficient
between VEGFA levels and platelet counts was significant
(r = 036, P = 0001). As platelets are the main contributors
of serum VEGF and ITP patients have lower platelet counts
per se, detection of VEGFA in protein level from serum or
plasma samples may cause biological bias. Therefore, we per-
formed quantitative gene expression analysis from PBMC of
12 active ITP patients (platelet count median, 34  33 9
109/l) and 12 healthy donors (platelet counts greater than
250 9 109/l). As shown in Fig 3A, compared with healthy
controls, VEGFA mRNA expression was significantly
decreased in the PBMC of cITP patients (P = 0001, mean
cITP, 0042  0007 vs. mean healthy donors, 013  002).
Detection of anti-PCNA autoantibody using LIA
Proliferating cell nuclear antigen (PCNA) exhibited one of
the strongest changes in expression in the antibody
microarray experiment (17-fold change, adjusted P
value = 004). As several reports have indicated that sys-
temic autoimmune diseases with anti-PCNA autoantibody
have a high frequency of thrombocytopenia (Yamanaka &
Takasaki, 1993) and many nuclear proteins exhibited lower
expression levels in the microarray experiment, we analysed
a panel of autoantibodies closely related to autoimmunity
that could interfere with the antibody microarray experi-
ments. Sera from 20 controls and 40 patients were tested
for the following autoantibodies: PCNA, RNP68, RNPA,
RNPC, SmB, SmD, Ro/SSA60, Ro/SSA52 (TRIM21), La/
SSB, Rib-, CENP-B, scl70, Jo-1, histone, and dsDNA.
Autoantibodies against PCNA were detected in only 2 of 40
samples from cITP patients. Similarly, anti-RNPC, anti-Ro/
SSA52 (TRIM21) and La/SSB antibodies were each detected
in 2 patients, whereas none of the 20 healthy control sera
were positive for these autoantibodies. Anti-SmD and anti-
Ro/SSA60 autoantibodies were each detected in only one
patient and were not present in the control group
(Table III). Altogether, 9 out of 40 cITP patients were
Table I. List of 20 proteins with the largest decreases in expression
in patients with cITP.
Symbol Biological process FC adj.Pval
VEGFA Angiogenesis, differentiation 215 0010
CDKN2A Cell cycle 182 0013
BAX Apoptosis, host-virus interaction 181 0019
SELE Cell adhesion 174 0003
PCNA DNA damage, repair, and replication 170 0042
AIFM1 Apoptosis 166 0045
TG Thyroid hormones biosynthesis 160 0016
TFPI2 Blood coagulation 160 0006
EIF3B Protein biosynthesis 149 0000
ATP6V1F Hydrogen ion transport 133 0000
IFITM2 Antiviral defence, Innate immunity 131 0000
RP9 Cognition, RNA splicing 130 0029
EEF1G Protein biosynthesis 127 0000
GPX4 Oxidoreductase 127 0002
RPS2 Translation 126 0027
CASP10 Apoptosis 126 0013
MOXD1 Copper ion binding 126 0005
TPM2 Muscle contraction, regulation
of ATPase activity
126 0045
TGFBI Proliferation, differentiation 124 0011
RUNX3 Transcription regulation 124 0006
FC, fold change compared to healthy donors; adj.Pval., Benjamini-
Hochberg adjusted P-value.
Table II. List of the 20 proteins with the highest increases in expres-
sion in patients with cITP.
Symbol Biological process FC adj.Pval
EWSR1* Transcription regulation 239 0000
ZNF593 Transcription regulation 170 0003
EWSR1* Transcription regulation 149 0000
LAMTOR1 Cell growth regulation 139 0025
RPL10A Ribosomal protein 136 0020
HSPA1L Nucleotide binding, stress protection 135 0005
NR4A1 Transcription regulation 134 0020
SLC7A5 Amino acid transport 133 0000
NPY4R G protein coupled receptor
signalling pathway
132 0017
FUBP1 RNA binding 132 0000
CTSD Intracellular protein breakdown 128 0021
HNRNPR RNA binding 128 0009
BRPF3 Zinc ion binding 127 0004
SREBF1 Transcription regulation 126 0000
GRB10 Insulin receptor signalling pathway 125 0000
BRCA1 DNA repair 125 0007
THBS3 Cell adhesion 125 0010
DDIT3 Apoptosis, transcription regulation 124 0009
PGF Angiogenesis, differentiation 124 0000
HOXC11 Transcription regulation 124 0005
FC, fold change compared to healthy donors; adj.Pval, Benjamini-
Hochberg adjusted P-value.
*EWSR1 antibodies were redundantly spotted on microarray chips.
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positive for anti-nuclear antibodies, whereas none of the 20
controls exhibited any reactivity with the nuclear antigens
studied.
Analysis of RUNX3 and RUNX1 expression in platelets
of cITP patients and healthy controls
Runt-related transcription factor 3 (RUNX3) expression was
significantly decreased in the antibody microarray experi-
ments (adjusted P value = 0006). To validate this observa-
tion independently of changes in platelet counts among the
patient groups, we analysed RUNX3 protein expression in
platelet lysates of cITP patients and healthy controls using
Western blotting. As the RUNX family is a known regulator
of megakaryopoiesis, we additionally analysed the expression
of another member of the RUNX family, RUNX1, that was
not included in the antibody microarray. Western blot analy-
sis demonstrated decreased expression of RUNX3 in the pla-
telets of 50% of patients with refractory immune
thrombocytopenia (Fig 4). In contrast, an accumulation of
RUNX1 protein was detected in the platelets of most patients
with cITP and healthy controls (Fig 5).
RUNX3 and RUNX1 mRNA expression in PBMC of
cITP patients and healthy controls
Serum is comprised of proteins released from blood cells and
tissue. To determine if the results of the microarray tests can
be transferred to PBMC, we analysed RUNX3 and RUNX1
mRNA expression in the PBMC of cITP patients and healthy
controls using real time PCR. As shown in Fig 3A, although
RUNX3 mRNA expression was decreased in the PBMC of
cITP patients relative to internal ACTB expression
(0804  0155 vs. 1041  0102, cITP and controls, respec-
tively), the difference between both groups was not statisti-
cally significant (P = 0111). In contrast, RUNX1 analyses
demonstrated a statistically significant decreased mRNA
expression in PBMC of cITP patients compared with healthy
controls (P = 0001, mean 0243  0033 vs. 0651  0113,
cITP and controls, respectively; Fig 3A).
Fig 1. Comparative Venn analysis of differentially expressed proteins. Protein sets from separately analysed groups according to their disease
states and protein sets from unseparated analyses are compared. (ITP versus HD: protein set from unseparated analysis of all cITP patients versus
healthy controls; active versus HD: protein set from active chronic ITP group separately analysed versus healthy controls; remission versus HD:
protein set from chronic ITP patients in remission separately analysed versus healthy controls). ITP, immune thrombocytopenia; HD, healthy
donor.
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Discussion
Genome- and proteome-wide measurements of disease-speci-
fic alterations may help to obtain a more comprehensive
understanding of diseases. In addition to analysing DNA
aberrations and RNA expression (Sood et al, 2008; Makroo
et al, 2011), which may occasionally be useful for character-
izing diseases, systematic profiling of proteins is the method
of choice to ultimately identify principal components respon-
sible for the various in vivo physiological and pathological
processes. In our opinion, profiling of serum proteins (pro-
teomics) is currently the most promising method for disease
diagnosis and therapeutics for ITP and other autoimmune
diseases. Two-dimensional gel electrophoresis and mass spec-
trometry-based comparative proteomic approaches have been
widely used to discover biomarkers; however, these
approaches have some limitations, particularly in terms of
sensitivity, reproducibility, and resolution (Wittmann-Liebold
et al, 2006; Han et al, 2008). To overcome this limitation, we
preferred to apply the affinity-based proteomics approach
Fig 2. Heat map demonstrating unsupervised hierarchical clustering pattern of significantly differential expressed proteins. While samples from
active cITP patients and healthy controls built two distinct cluster patterns, the samples from cITP patients in remission are distributed amongst
both of these two clusters. Each row represents a single protein, and each column represents a single patient. Red represents increase expression;
green, decreased expression. The disease state of each sample was defined as either active (platelet count < 100 9 109/l), remission (platelet
count > 100 9 109/l) or healthy (platelet count > 250 9 109/l). cITP, chronic immune thrombocytopenia.
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Fig 3. Expression of VEGFA, RUNX1 and RUNX3. (A) Relative expression of VEGFA, RUNX1 and RUNX3 mRNA in PBMC of active cITP
patients (n = 12) and healthy controls (n = 12). Results are shown as expression of the target genes in comparison to internal expression of the
housekeeping gene ACTB. (B) Serum protein concentration of vascular endothelial growth factor (VEGFA). The sera from 33 healthy controls
and 46 patients with cITP, composed of 33 patients with active disease and 13 patients in remission, were analysed by ELISA for the presence of
VEGFA. pt, P-value from student t-test; pMWU, P-value from Mann–Whitney-U-test; *001 ≤ P < 005; **0001 ≤ P < 001;
***00001 ≤ P < 0001; ****P < 00001.
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(antibody-based microarray) that is frequently applied in
cancer research and diagnostics because of the sensitivity of
the technique and its similarity to routinely applied affinity
assay formats (Alhamdani et al, 2009; Hoheisel et al, 2013).
Protein biomarkers have improved the management of
different diseases (Parker & Borchers, 2014). Focusing on
ITP, we sought to determine whether particular proteins are
involved in both ITP and malignancies. In fact, a bidirec-
tional association between ITP and malignancies has been
reported; ITP occurs in patients with malignancies and cITP
patients may develop haematological disorders (Liebman,
2009; Norgaard et al, 2011; Krauth et al, 2012). Using the
antibody microarray described in this study, 165 antibodies
yielded significantly different signal intensities, corresponding
to 161 distinct proteins that showed significantly different
expression in cITP. In agreement with the association of ITP
and malignancies, many oncoproteins and tumour-suppres-
sor proteins exhibited significantly different expression in
cITP, including TRIP13, BRCA1, FANCC, BCL2 and BCAS1.
To date, numerous studies have indicated that the aetiol-
ogy and disease status of ITP is closely related with an
impaired balance of T helper cytokines (Th1/Th2) and T reg-
ulatory cell cytokines (Th3), but the reported data are mostly
controversial (Ogawara et al, 2003; Ma et al, 2008) and some
are contradictory (Panitsas et al, 2004; Ma et al, 2014). Simi-
lar to the finding in the most recent study (Ma et al, 2014),
we observed a significantly downregulated protein concentra-
tion of Th1 cytokines, interleukin (IL)2, IL6 and IFNG (only
in active disease states) in the serum of cITP patients. Dis-
crepancy with some of the studies might be due to the
heterogenetic aetiology of ITP or the nature of the exclusion
diagnosis in ITP. These were sustained by hierarchical cluster
analysis of our antibody microarray data, where some of the
ITP patients were distributed independently from their dis-
ease state between healthy controls and active states. In con-
trast to Th1 cytokines, the Th3 cytokine, transforming
growth factor-b1 (TGFB1), which is associated with an
immunosuppressive profile, were consistently reported by
several studies downregulated in ITP (Andersson et al, 2000,
2002). A significantly decreased TGFB1 concentration was
also detected in the serum of patients using our antibody
microarray. Consistent with this finding, it has been reported
that decreased TGFB1 is correlated with deficient frequency
and function of CD4⁺CD25⁺FOXP3⁺ regulatory T cells in
patients with immune thrombocytopenia (Fahim & Monir,
2006; Arandi et al, 2014).
Separate analysis of patients with active and remission
states yielded significant differences of 134 distinct proteins
in the active cITP group, whereas 126 of these were differen-
tially expressed in both groups when combined. The detec-
tion of 126 mutual proteins indicates an accurate processing
of samples and robustness of the antibody microarray data.
However, differences in the expression levels of some
proteins may occur between the individual disease states,
active or remission. Interestingly, 8 distinct proteins were
Table III. Results of the analysis of sera from 20 healthy donors and
40 patients with cITP tested for the presence of fifteen nuclear
autoantibodies. Only those patients with detectable autoantibodies
are shown. There were no patients or healthy donors expressing
antibodies against RNP68, RNPA, SmB, Rib-P, CEBP-B, scl70, jo-1,
Histon or dsDNA.
Patient RNPC SmD Ro/SSA60 Ro/SSA52 La/SSB PCNA
1 +     
2      
3     + 
4     + 
5   + +  
6 +     
7      +
8      +
9  +    
Fig 4. Protein expression of RUNX3 in platelets of cITP patients
(n = 14) versus healthy controls (n = 8) were analysed using Western
blot assays (ACTB as loading control). cITP, chronic immune
thrombocytopenia
Fig 5. RUNX1 protein expression in platelets from patients with
cITP (n = 18) versus healthy controls (n = 15) was analysed using
Western blot assays (HSPA8 is the loading control).
G. Bal et al
610 ª 2015 John Wiley & Sons Ltd
British Journal of Haematology, 2016, 172, 602–615
significantly differentially expressed only in the active disease
state and comprised of FGF2, MMP10, IFNG, IFIT2, ICAM2,
NME2, CCNG1 and BCL2 (Fig 1). Consistent with our
results, the apoptosis regulator BCL2 was found to be upreg-
ulated in sera from children and adult cITP patients (Liu
et al, 2005; Stasi et al, 2007). In agreement with other studies
(Olsson et al, 2005; Chang-Lin et al, 2007), our results indi-
cate that impaired apoptosis in patients with active ITP
could be involved in active platelet destruction. Therefore,
specific inhibition of BCL2 activity might achieve remission
of ITP.
To evaluate the reliability of microarray analysis, we con-
firmed the results of the VEGFA concentration by ELISA.
Microarray data were validated even with an alternative
cohort, thus indicating a robust finding. Similar to the
decreased levels of VEGFA identified with the antibody
microarray, serum levels of VEGFA in patients with active
ITP were significantly decreased (median, 196 pg/ml) com-
pared with healthy controls (median, 648 pg/ml) by ELISA.
Moreover, a significant correlation was observed between
VEGFA levels and platelet counts (r = 036, P = 0001).
Although the ELISA demonstrated the reliability of the anti-
body microarray experiments, it is unclear whether VEGFA
plays a role in the pathophysiology of cITP. The decreased
concentration and positive correlation of VEGFA may be
explained first by the lower platelet counts in patients with
cITP and large amounts of VEGFA in platelet granules (Gun-
silius et al, 1999). However, independent of platelet counts,
significant changes in VEGFA expression in peripheral
blood-derived T cells of patients with cITP have been
detected at the transcriptional level (Jernas et al, 2013). Con-
sistent with this finding, downregulated VEGFA mRNA levels
were also detected in the PBMC of 12 cITP patients versus
12 healthy donors. In addition, increased soluble FLT1 con-
centrations (P < 005), a receptor for VEGFA, were detected
in the serum of patients with cITP using the antibody
microarray. Increased levels of soluble FLT1 may interfere
with VEGFA and FLT1 interaction on megakaryocytes and
may significantly inhibit megakaryocytic polyploidization
(Casella et al, 2003), which is correlated with cITP develop-
ment (Gerritsma et al, 1994). Another ligand of FLT1 is pla-
cental growth factor (PGF) and its expression was
significantly increased (adjusted P-value < 1016) in the sera
of patients with cITP. Altogether, the altered concentrations
of VEGFA, PGF and soluble FLT1 in patient groups indicate
that a deregulated VEGF signalling pathway contributes to
the pathophysiology of cITP. In agreement with this finding,
increased PGF concentrations were used as a biomarker by
Young et al (2010) to distinguish patients with ITP from
patients with thrombocytopenia resulting from HELLP
(haemolysis, elevated liver enzymes, and low platelets) syn-
drome during pregnancy.
A potential role of the RUNX family in the development
of chronic autoimmune diseases, such as systemic lupus ery-
thematosus (SLE), rheumatoid arthritis (RA) and psoriasis,
has been reported by several authors (Helms et al, 2003;
Tokuhiro et al, 2003; Alarcon-Riquelme, 2004). RUNX1 and
RUNX3 have primarily been found to regulate genes
expressed in the myeloid and lymphoid lineages (Otto et al,
2003). The targets of RUNX1 include B-cell specific tyrosine
kinase (BLK), the T-cell antigen receptor (TCR) a, b, c and
d chains, CD3, CD4, and granulocyte/macrophage colony
stimulating factor (GM-CSF) in lymphoid cells (Otto et al,
2003). Moreover, RUNX3 and RUNX1 are required for CD8
T cell development during thymopoiesis (Woolf et al, 2003),
and the regulatory T cell function is controlled by the
interaction between FOXP3 and RUNX1 (Ono et al, 2007).
A variety of abnormalities within the T cell population in
ITP have been described (Semple & Freedman, 1991; Garcia-
Suarez et al, 1993; Semple et al, 1996), including increased
autoreactive T cell reactivity and decreased regulatory T cell
function (Kuwana et al, 1998). We hereby present a statisti-
cally significant downregulation of RUNX1 mRNA expression
in the PBMC of cITP that may lead to the variety of T cell
abnormalities observed in cITP. A similar, but not statisti-
cally significant, downregulation of RUNX3 mRNA expres-
sion in the PBMC of most cITP was observed. Furthermore,
we provide evidence for deregulated RUNX3 and RUNX1
appearance in platelets of cITP patients. In particular,
RUNX1 accumulation in the platelet cytoplasm may indicate
disturbed nuclear transport mechanisms in megakaryocytes
in cITP patients. In addition to the immune-mediated
destruction of platelets, megakaryocytic abnormalities, such
as altered megakaryocytic maturation, are suggested to be
one of the main pathogenic abnormalities in cITP (Gerritsma
et al, 1994; Ucar et al, 2003). In this respect, the disturbed
nuclear transport of RUNX1 may result in inadequate
thrombopoiesis through aberrant expression of the throm-
bopoietin receptor, MPL, in megakaryocytes. Indeed, MPL in
myeloid lineage cells and megakaryocytes is controlled by
RUNX1 (Satoh et al, 2008; Yu et al, 2012). Moreover,
RUNX1 is a key regulator for the switch of mitosis to
endomitosis in megakaryocytes, linking polyploidization and
megakaryocyte differentiation (Lordier et al, 2012).
Several authors have reported that a subpopulation of
patients with ITP has autoantibodies to nuclear proteins and
is at risk for developing SLE (Balsalobre Aznar et al, 1999;
Unal et al, 2005; Hazzan et al, 2006). Conversely, anti-plate-
let antibodies have been detected in 78% of SLE patients,
often without accompanied thrombocytopenia, and in up to
16% of these patients, isolated thrombocytopenia was the
initial clinical manifestation (Yehudai et al, 2013). The differ-
ential diagnosis of cITP and secondary ITP in cases of SLE
has prognostic implications. One of the potential prognostic
factors, PCNA, had significantly decreased expression in the
cITP group. To confirm this finding, we investigated a panel
of autoantibodies; anti-PCNA is closely related to systemic
autoimmunity and could have interfered with our antibody
microarray experiments. However, anti-PCNA autoantibody
was detected in only 2 of 40 cITP patients using LIA. These
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two patients were also included in the microarray analysis. In
addition, we detected the anti-RNPC, anti-Ro/SSA52 and
anti-La/SSB autoantibodies in two different cases. Altogether,
9 of 40 patients with cITP were positive for anti-nuclear
antibodies, whereas none of the 20 control sera exhibited any
reactivity with the nuclear antigens studied. As ITP may
occur as a first manifestation of other immune systemic dis-
eases, screening these factors in patients with ITP may be
useful for the early recognition of patients at risk for pro-
gression to other diseases, facilitating the choice of therapeu-
tic procedures (Adachi et al, 1990; Balsalobre Aznar et al,
1999). On the other hand, the presence of autoantibodies in
the serum of ITP patients may have a great impact on the
outcome of antibody microarrays. Autoantibodies in the
serum of a patient may cause sequestration of their target
proteins in vivo. More importantly, autoantibodies in serum
samples may cause depletion of their targeted proteins from
the protein pool (as a common protein reference, described
in Material and methods) on each microarray chip. We
detected anti-PCNA serum reactivity in two patients in our
collective patient group, leading to the conclusion that the
significantly downregulated PCNA protein expression
detected in our microarray is not representative. Although
this would be a technical bias, a controversial interpretation
of downregulated proteins similar to our experience with
anti-PCNA might help to detect novel autoantibodies in ITP.
The cyclin-dependent kinase (CDK) inhibitor gene
CDKN2A (P16INK4) is an important tumour suppressor
gene, which controls the checkpoint of the cell cycle at the
G1/S phase transition and has a pivotal function in the
induction of apoptosis and senescence, as well as quiescence,
of cell cycles (Nobori et al, 1994; Stone et al, 1995). A senes-
cence-like process was also detected in the physiological
post-mitotic megakaryocytes, which is a contribution of
CDK inhibitors induced by thrombopoietin (Besancenot
et al, 2010). Moreover, CDKN2A has been reported to affect
the expression of inflammatory cytokines from activated
macrophages (Taniguchi et al, 1999; Murakami et al, 2012).
We observed significantly decreased CDKN2A protein
expression in the serum of a cITP patient using antibody
microarray (087-fold change, adjusted P-value = 001).
Accordingly, increased expression of BMI1 protein, a tran-
scriptional repressor of CDKN2A, was recently reported in
the autoreactive T-cells of active ITP patients (Ma et al,
2012). Loss of RUNX1 in mouse BM cells was also shown to
induce enhanced BMI1 expression (Nishimoto et al, 2011).
Therefore, down-regulation of CDKN2A in cITP patients
may be a consequence of BMI1 up-regulation by dysregu-
lated RUNX1 mRNA expression. Alterations in the expres-
sion of RUNX1 itself may have similar effects. It is
noteworthy that EWSR1 is inversely associated with
CDKN2A expression (Cho et al, 2011), whereas EWSR1
exhibited increased expression (126-fold change, adjusted P-
value < 1016) in the present study. Overall, we suggest that
a possible interplay between EWSR1, CDKN2A and RUNX
in the context of cellular senescence may contribute to the
pathophysiology of cITP.
In conclusion, we present numerous differentially
expressed proteins in cITP that may be useful as a starting
point for decoding the aetiology and pathogenesis of ITP.
We also identified new factors and mechanisms, such as
deregulated VEGFA signalling pathway, deregulated cellular
senescence and apoptosis, and dysregulated expression of
RUNX1 that appears to play a role in ITP. Future studies are
required to further characterize these findings.
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